drugset / Trial / NCT04399876
Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Prostate Cancer
Phase 1
Enrolling by invitation
35 enrolled
Brigham and Women's Hospital
National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
In this research study, is assessing the feasibility of using an MR-guided implantable microdevice to measure tumor response to chemotherapy and other clinically relevant drugs in participants that have prostate cancer and are scheduled for a radical prostatectomy. The name of the study intervention involved in this study is: \- Implantation of a MR-guided microdevice
Timeline
- Start
- 2020-06-22
- Primary completion
- 2027-08-01
- Completion
- 2027-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | — | — |
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Enzalutamide | Other / unclassified | — | — |
| Subject | Ipilimumab | Monoclonal antibody | — | — |
| Subject | Olaparib | Small molecule | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |